Healthcare entity
Clarity Pharmaceuticals is most often covered alongside 4D Medical, which appears in 1 of these 2 stories. That works out to roughly 0.5 stories per week across a 29-day span. Each story carries 3.5 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Clarity Pharmaceuticals is most often covered alongside 4D Medical, which appears in 1 of these 2 stories. That works out to roughly 0.5 stories per week across a 29-day span. Each story carries 3.5 original sources on average, compared with 3.3 for the broader beat in this window. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. At 6, the average consequence score sits above the same-window beat average of 5.9. This profile follows 2 Healthcare stories mentioning Clarity Pharmaceuticals across the period from February 25, 2026 to March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 608 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Clarity Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Phase III Milestones
Anticipated data readouts for TCT imaging agents supported by Cu-64 supply.
Supply Chain Integration
Integration of Theragenics' output into Clarity's clinical trial logistics.
Supply Agreement Signed
Clarity and Theragenics formalize large-scale Cu-64 manufacturing partnership.
Clarity Pharmaceuticals has entered into a multi-year manufacturing supply agreement with Theragenics for the production of copper-64 (Cu-64). This partnership secures a reliable, large-scale supply of the isotope to support Clarity's clinical trials and future commercialization of its Targeted Copper Theranostics platform.
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.
Source: 0 Comments (au) · 0 Comments (au)
Clarity Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
